Quick Facts
| CAS Number | 39831-55-5 |
|---|---|
| Molecular Formula | C22H47N5O21S2 |
| Molecular Weight | 781.76 |
| Pharmacopoeia | USP, EP, CP |
| Packaging | 25 KG/DRUM |
USP Standard
EP/BP Standard
GMP Certified
Product Overview
Amikacin Sulfate is a semisynthetic aminoglycoside antibiotic derived from kanamycin. It has the broadest spectrum among aminoglycosides and is resistant to most aminoglycoside-inactivating enzymes, making it a critical agent in human medicine.
Amikacin inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. It is a first-line treatment for serious Gram-negative infections, including those caused by multidrug-resistant organisms (MDROs) such as ESBL-producing Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii.
Quality Specifications
| Purity | As per USP monograph |
|---|---|
| Residual Solvents | Compliant with ICH Q3C |
| Heavy Metals | Compliant with pharmacopoeia limits |
| GMP Status | Manufactured under GMP conditions |
Pharmaceutical Applications
- Hospital-acquired pneumonia: Including ventilator-associated pneumonia (VAP)
- Complicated urinary tract infections: Including pyelonephritis
- Septicemia: Severe Gram-negative bacteremia and sepsis
- Multidrug-resistant tuberculosis: Second-line agent for MDR-TB
- Febrile neutropenia: Empiric therapy in immunocompromised patients
Standards: USP, EP, CPV | CAS: 39831-55-5 (Base) / 149022-22-0 (Sulphate) | Quality data verified against pharmacopoeia monograph
COA and MSDS available | DrugBank | June 2026